Mirshahidi Hamid R, Mirshahidi Saied
Loma Linda University Cancer Center - Hematology/Oncology, 11175 Campus St. CSP, Loma Linda, California 92354, USA.
Expert Rev Anticancer Ther. 2015 Apr;15(4):375-85. doi: 10.1586/14737140.2015.1025761.
The US FDA granted approval for crizotinib as the first-line treatment for patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013. Crizotinib is a customized and improved therapeutic option for patients with non-small-cell lung cancer that enhances overall survival without increasing toxicity. In the future, new targeted therapies may achieve additional indications for treating patients with lung cancer. This article summarizes data from crizotinib studies.
2013年11月20日，美国食品药品监督管理局批准克唑替尼作为棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶重排转移性非小细胞肺癌患者的一线治疗药物。克唑替尼是一种针对非小细胞肺癌患者的定制化改良治疗选择，可提高总生存期且不增加毒性。未来，新的靶向治疗可能会获得更多治疗肺癌患者的适应症。本文总结了克唑替尼研究的数据。
